Author | John Jesitus


Bimekizumab phase 3 data reflect rapid, durable response

June 29, 2020

Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.

More treatment options emerging for acne, rosacea

June 17, 2020

In the last three to five years, there has been a tremendous increase in interest in prescription treatments for acne and rosacea, resulting in many promising products entering the marketplace for these conditions.

Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies

April 24, 2020

The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.

Biologic guidelines for psoriasis let providers choose

April 24, 2020

When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.